Abstract:Importance: Serious cutaneous adverse drug reactions (cADRs) are potentially life-threatening drug hypersensitivity reactions involving the skin and internal organs. Antibiotics are a recognized cause of these reactions, but no studies have compared relative risks across antibiotic classes. Objectives: To explore the risk of serious cADRs associated with commonly prescribed oral antibiotics, and to characterize outcomes of patients hospitalized for them. Design, setting, and participants: Nested case-control study using population-based linked administrative datasets among adults aged 66 years or older who received at least 1 oral antibiotic between 2002 and 2022 in Ontario, Canada. Cases were those who had an emergency department (ED) visit or hospitalization for serious cADRs within 60 days of the prescription, and each case was matched with up to 4 controls who did not. Exposure: Various classes of oral antibiotics. Main outcomes and measures: Conditional logistic regression estimate of the association between different classes of oral antibiotics and serious cADRs, using macrolides as the reference group. Results: During the 20-year study period, we identified 21 758 older adults (median age, 75 years; 64.1% female) who had an ED visit or hospitalization for serious cADRs following antibiotic therapy and 87 025 matched controls who did not. In the primary analysis, sulfonamide antibiotics (adjusted odds ratio [aOR], 2.9; 95% CI, 2.7-3.1) and cephalosporins (aOR, 2.6; 95% CI, 2.5-2.8) were most strongly associated with serious cADRs relative to macrolides. Additional associations were evident with nitrofurantoin (aOR, 2.2; 95% CI, 2.1-2.4), penicillins (aOR, 1.4; 95% CI, 1.3-1.5), and fluoroquinolones (aOR, 1.3; 95% CI, 1.2-1.4). The crude rate of ED visits or hospitalization for cADRs was highest for cephalosporins (4.92 per 1000 prescriptions; 95% CI, 4.86-4.99) and sulfonamide antibiotics (3.22 per 1000 prescriptions; 95% CI, 3.15-3.28). Among the 2852 case patients hospitalized for cADRs, the median length of stay was 6 days (IQR, 3-13 days), 9.6% required transfer to a critical care unit, and 5.3% died in the hospital. Conclusion and relevance: Commonly prescribed oral antibiotics are associated with an increased risk of serious cADRs compared with macrolides, with sulfonamides and cephalosporins carrying the highest risk. Prescribers should preferentially use lower-risk antibiotics when clinically appropriate.

Low-risk cefalexin allergies are associated with inpatient prescribing of second-line non-beta-lactam antibiotics

Removing penicillin allergy label in a hospitalized adolescent with a remote penicillin and recent cephalosporin allergy

Safe Medication Use Based on Knowledge of Information about Contraindications Concerning Cross Allergy and Comprehensive Clinical Intervention

[A multicenter clinical study on the incidence and influencing factors of cephalosporin-induced anaphylaxis]

Documentation of penicillin adverse drug reactions in electronic health records: inconsistent use of allergy and intolerance labels

Proactive management of penicillin and other antibiotic allergies

Oral Antibiotics and Risk of Serious Cutaneous Adverse Drug Reactions

The Safety of Aztreonam Versus Ceftazidime in Patients Labeled With Penicillin Allergy: A Cohort Study

The impact of antibiotic allergy labels on antibiotic exposure, clinical outcomes, and healthcare costs: A systematic review

Beta‐lactam allergy risk stratification in a maternity population in Australia: Scope for allergy de‐labelling

[Reevaluation of penicillin allergy labeling, appropriate use of β-lactam antibiotics, and multidrug resistance]

Examining cefazolin utilization and perioperative anaphylaxis in patients with and without a penicillin allergy label: A cross-sectional study

Are changes in antibiotic prophylaxis recommendations responsible for an increased risk of cefazolin allergy?

Delabelling beta-lactam allergy

Introduction of a penicillin allergy de-labelling program with direct oral challenge and its effects on utilization of beta-lactam antimicrobials: a multicenter retrospective parallel cohort study

567. The Quality & Management of Penicillin Allergy Labels in a Pediatric Birth Cohort

Is the Anamnesis Enough to De-Label Patients with Reported Beta-Lactam Allergy?

Safe Penicillin Allergy Delabeling in Primary Care: A Systematic Review and Meta-Analysis

Retrospective study on penicillin allergy delabeling and evaluation of an antibiotic allergy assessment tool

The appropriateness of penicillin allergy de-labelling by non-allergist clinical ward teams

1332. Single Dose Oral Amoxicillin Challenge is a Safe and Effective Strategy to Delabel Penicillin Allergies among Low Risk Hospitalized Children